Viral Genetics, Inc. (VRAL) shares jumped more than 30 percent, as the stock broke out on unusually high volume. Investors are speculating that the company’s pre-clinical cancer, Lyme disease and HIV drugs will eventually become a big success.
Viral Genetics, Inc. (VRAL.PK: 0.065 +35.42%), a biopharmaceutical company engaged in the development of drugs to treat cancer, [...]